EAN 2022 | Prognostic value of baseline sNfL on treatment effect of evobrutinib
Evobrutinib, a selective oral BTK inhibitor, has been shown to significantly reduce enhancing lesions, compared to placebo, in a Phase II randomized trial in patients with relapsing MS. High-dose evobrutinib was also shown to significantly reduce serum neurofilament light (sNfL) levels at weeks 12 and 24 after treatment initiation. Jens Kuhle, MD, PhD, University Hospital Basel, Basel, Switzerland, shares the finding of a post-hoc analysis evaluating the prognostic value of baseline sNfL levels on clinical relapse and MRI lesion activity. Over 160 patients were analyzed, demonstrating that higher baseline sNfL was associated with greater MRI lesion activity and more clinical relapses over the 24 weeks. Compared to placebo, high-dose evobrutinib significantly reduced relapses when stratified by baseline sNfL (low versus high) and reduced both new/enlarging T2 lesions, and the cumulative number of GAD-enhancing lesions. This interview took place at the European Academy of Neurology (EAN) 2022 Congress in Vienna, Austria.
Transcript (edited for clarity)
Yeah, so this was on the Phase II evobrutinib study. Approximately 170 patients provided samples for serum neurofilament light chain measurements. This was a study versus placebo or low dose evobrutinib and high dose evobrutinib. We had seen earlier that high dose evobrutinib showed a significant reduction of serum neurofilament light levels, I think as early as six weeks after starting the treatment...
Yeah, so this was on the Phase II evobrutinib study. Approximately 170 patients provided samples for serum neurofilament light chain measurements. This was a study versus placebo or low dose evobrutinib and high dose evobrutinib. We had seen earlier that high dose evobrutinib showed a significant reduction of serum neurofilament light levels, I think as early as six weeks after starting the treatment. This work here was now looking at prognostic value of baseline serum NfL levels on new T2 lesions, gadolinium lesions, and relapses, and we saw a clear signal that patients with higher NfL at baseline also showed more gadolinium activity, more new T2 lesion activity, and more relapses over the six months study later on. And we also saw that high dose evobrutinib significantly reduced these endpoints independent of having high or low NfL levels at baseline.
Read more...
